Grant: Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
Unity Health Toronto
$135,000.00
Psilocybin-Assisted Intensive Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial
EF 2023-24
Résumé
Posttraumatic stress disorder (PTSD) affects over 2.5 million adults in Canada, current front-line treatments (antidepressants/psychotherapy) remain ineffective for up to one-thirds of these Canadians with PTSD. Novel rapid-acting treatments with demonstrated efficacy are needed to promote well-being of Canadians living with PTSD. Psilocybin-assisted cognitive processing therapy (CPT) may be a potential solution. Psilocybin is a serotonin receptor agonist with therapeutic potential for various psychiatric conditions. We will administer 1 week of intensive CPT combined with a single dose psilocybin 25 mg in participants with chronic PTSD recruited at St. Michael's hospital. This funded trial is the first worldwide to evaluate psilocybin-assisted intensive CPT for PTSD. The primary outcomes are feasibility, tolerability; the secondary outcome is efficacy of psilocybin-assisted CPT on PTSD symptoms. Positive results with normalization of symptoms will result in accelerated definitive studies for breakthrough treatment development for PTSD.
Programme
Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Other
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
497743
Name
Meshkat Shakila
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Psilocybin-Assisted Intensive Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial
Programtype2
Fellowship Programs
Orgnameinp2
Unity Health Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Pandemic Preparedness and Health Emergencies
Keyworddelim
Clinical Trial; Data Analysis; Intensive Cognitive Processing Therapy; Open-Label Trial; Posttraumatic Stress Disorder; Psilocybin; Psychedelic-Assisted Therapy; Qualitative Interview; Therapeutic Efficacy; Trauma Treatment
Abstract
Posttraumatic stress disorder (PTSD) affects over 2.5 million adults in Canada, current front-line treatments (antidepressants/psychotherapy) remain ineffective for up to one-thirds of these Canadians with PTSD. Novel rapid-acting treatments with demonstrated efficacy are needed to promote well-being of Canadians living with PTSD. Psilocybin-assisted cognitive processing therapy (CPT) may be a potential solution. Psilocybin is a serotonin receptor agonist with therapeutic potential for various psychiatric conditions. We will administer 1 week of intensive CPT combined with a single dose psilocybin 25 mg in participants with chronic PTSD recruited at St. Michael's hospital. This funded trial is the first worldwide to evaluate psilocybin-assisted intensive CPT for PTSD. The primary outcomes are feasibility, tolerability; the secondary outcome is efficacy of psilocybin-assisted CPT on PTSD symptoms. Positive results with normalization of symptoms will result in accelerated definitive studies for breakthrough treatment development for PTSD.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Meshkat, Shakila
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
